Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril

References

• AtlasSAThe renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibitionJ Manag Care Pharm2007138 Suppl B92017970613
   PubMed Web of Science ®Google Scholar
• MontaniJPVan VlietBNGeneral physiology and pathophysiology of the renin-angiotensin systemUngerTSchölkensBAAngiotensinIIHeidelbergSpringer2004548
   Google Scholar
• DzauVThe cardiovascular continuum and renin-angiotensin-aldosterone system blockadeJ Hypertens Suppl2005231S9S1715821452
   PubMedGoogle Scholar
• UngerTThe role of the renin-angiotensin system in the development of cardiovascular diseaseAm J Cardiol2002892A3A9A
   PubMed Web of Science ®Google Scholar
• AsmarRTelmisartan in high cardiovascular risk patientsEur Cardiol Rev2012811016
   Google Scholar
• SchmiederREHilgersKFSchlaichMPSchmidtBMRenin-angiotensin system and cardiovascular riskLancet200736995681208121917416265
   PubMed Web of Science ®Google Scholar
• VerdecchiaPGentileGAngeliFReboldiGBeyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockersTher Adv Cardiovasc Dis201262819122528743
   PubMedGoogle Scholar
• [No authors listed]KDIGO clinical practice guideline for the management of blood pressure in chronic kidney diseaseKidney Int Suppl201225338414
   Web of Science ®Google Scholar
• BerlTAngiotensin-converting enzyme inhibitors versus AT1 receptor antagonist in cardiovascular and renal protection: the case for AT1 receptor antagonistJ Am Soc Nephrol200415Suppl 1S71S7614684677
   PubMed Web of Science ®Google Scholar
• PoulterNARBs in hypertensionBr J Cardiol201017s6s9
   Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2013Diabetes Care201336Suppl 1S11S6623264422
   PubMed Web of Science ®Google Scholar
• ManciaGFagardRNarkiewiczK2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)Eur Heart J201331712811357
   Google Scholar
• McMurrayJJAdamopoulosSAnkerSDESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEur Heart J201233141787184722611136
   PubMed Web of Science ®Google Scholar
• Servier LaboratoriesCoversyl (arginine): summary of product characteristicsNeuilly-sur-Seine, FranceServier Laboratories2009
   Google Scholar
• Boehringer IngelheimMicardis (telmisartan) tablets [prescribing information]Ingelheim, GermanyBoehringer Ingelheim2011
   Google Scholar
• MaillardMPPerregauxCCentenoCIn vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonistJ Pharmacol Exp Ther200230231089109512183667
   PubMed Web of Science ®Google Scholar
• BattershillAJScottLJTelmisartan: a review of its use in the management of hypertensionDrugs2006661518316398568
   PubMed Web of Science ®Google Scholar
• HurstMJarvisBPerindopril: an updated review of its use in hypertensionDrugs200161686789611398915
   PubMed Web of Science ®Google Scholar
• SharpeMJarvisBGoaKLTelmisartan: a review of its use in hypertensionDrugs200161101501152911558835
   PubMed Web of Science ®Google Scholar
• ThomsonAGreenacreMPerindopril: the evidence of its therapeutic impact in hypertensionCore Evid200721637921221198
   PubMedGoogle Scholar
• ToddPAFittonAPerindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disordersDrugs1991421901141718688
   PubMed Web of Science ®Google Scholar
• NalbantgilINalbantgilSOzerkanFThe efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertensionInt J Clin Pract Suppl2004145505415617460
   PubMedGoogle Scholar
• RagotSEzzaherAMeunierAPoterreMBourkaibRHerpinDComparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE studyJ Hum Hypertens2002161286587312522468
   PubMed Web of Science ®Google Scholar
• GhiadoniLMagagnaAVersariDDifferent effect of antihypertensive drugs on conduit artery endothelial functionHypertension20034161281128612719441
   PubMed Web of Science ®Google Scholar
• PengXLinZZhaoYHuangPEffect of telmisartan on left ventricular hypertrophy in elderly patients with diabetes mellitus and essential hypertensionZhonghua Lao Nian Yi Xue Za Zhi2005246435437
   Google Scholar
• RemkováAKratochvíl’ovaHDurinaJImpact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertensionJ Hum Hypertens200822533834518305548
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative GroupRandomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attackLancet200135892871033104111589932
   PubMed Web of Science ®Google Scholar
• ClelandJGTenderaMAdamusJFreemantleNPolonskiLTaylorJThe perindopril in elderly people with chronic heart failure (PEP-CHF) studyEur Heart J200627192338234516963472
   PubMed Web of Science ®Google Scholar
• DahlofBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet2005366948989590616154016
   PubMed Web of Science ®Google Scholar
• FerrariREffects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) studyArch Intern Med2006166665966616567606
   PubMedGoogle Scholar
• FoxKMEfficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, doubleblind, placebo-controlled, multicentre trial (the EUROPA study)Lancet2003362938678278813678872
   PubMed Web of Science ®Google Scholar
• PatelAMacMahonSChalmersJEffects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trialLancet2007370959082984017765963
   PubMed Web of Science ®Google Scholar
• YusufSTeoKAndersonCEffects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trialLancet200837296441174118318757085
   PubMed Web of Science ®Google Scholar
• YusufSDienerHCSaccoRLTelmisartan to prevent recurrent stroke and cardiovascular eventsN Engl J Med2008359121225123718753639
   PubMed Web of Science ®Google Scholar
• YusufSTeoKKPogueJTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• YusufSSleightPPogueJBoschJDaviesRDagenaisGEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study InvestigatorsN Engl J Med2000342314515310639539
   PubMed Web of Science ®Google Scholar
• StaessenJAWangJBlood-pressure lowering for the secondary prevention of strokeLancet200135892871026102711589927
   PubMed Web of Science ®Google Scholar
• BeckettNSPetersRFletcherAETreatment of hypertension in patients 80 years of age or olderN Engl J Med2008358181887189818378519
   PubMed Web of Science ®Google Scholar
• BeckettNPetersRTuomilehtoJImmediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trialBMJ2012344d754122218098
   PubMedGoogle Scholar
• ManciaGLaurentSAgabiti-RoseiEReappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force documentJ Hypertens200927112121215819838131
   PubMed Web of Science ®Google Scholar
• KaplanNMVascular outcome in type 2 diabetes: an ADVANCE?Lancet2007370959080480517765962
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436394262022203115207952
   PubMed Web of Science ®Google Scholar
• WeberMAJuliusSKjeldsenSEBlood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE TrialLancet200436394262049205115207957
   PubMed Web of Science ®Google Scholar
• WilliamsBLacyPSThomSMDifferential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) studyCirculation200611391213122516476843
   PubMed Web of Science ®Google Scholar
• JamersonKWeberMABakrisGLBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsN Engl J Med2008359232417242819052124
   PubMed Web of Science ®Google Scholar
• NeldamSEdwardsCTelmisartan plus HCTZ vs amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring studyAm J Geriatr Cardiol200615315116016687967
   PubMedGoogle Scholar
• NeutelJMManciaGBlackHRSingle-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN studyJ Clin Hypertens (Greenwich)201214420621522458741
   PubMed Web of Science ®Google Scholar
• SharmaAMDavidsonJKovalSLacourciereYTelmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH studyCardiovasc Diabetol200762817910747
   PubMed Web of Science ®Google Scholar
• European CommissionAnnex II: Scientific conclusions and grounds for amendment of the summary of product characteristics presented by the EMEA Available from: http://ec.europa.eu/health/documents/community-register/2005/2005110710227/anx_10227_en.pdfAccessed February 28, 2014
   Google Scholar
• McInnesGTTelmisartan to prevent recurrent stroke: the PRoFESS study: was the baby thrown out with the bathwater?Stroke20094051938194019038906
   PubMed Web of Science ®Google Scholar
• AdamsHPJrdelZGAlbertsMJGuidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologistsStroke20073851655171117431204
   PubMed Web of Science ®Google Scholar
• MannJFSchmiederREMcQueenMRenal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trialLancet2008372963854755318707986
   PubMed Web of Science ®Google Scholar
• DagenaisGRVascular protection: telmisartan in the ONTARGET trial programmeEur Heart J Suppl200911Suppl FF47F53
   Web of Science ®Google Scholar
• ZouZXiGLYuanHBZhuQFShiXYTelmisartan versus angiotension [sic]-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trialsJ Hum Hypertens200923533934918987649
   PubMed Web of Science ®Google Scholar
• DolanEStantonAThijsLSuperiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome studyHypertension200546115616115939805
   PubMed Web of Science ®Google Scholar
• WhiteWBAmbulatory blood pressure as a predictor of target organ disease and outcome in the hypertensive patientBlood Press Monit199943–418118410490872
   PubMedGoogle Scholar
• TurnbullFEffects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsLancet200336293951527153514615107
   PubMed Web of Science ®Google Scholar
• WangJGLiYFranklinSSSafarMPrevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: a quantitative overviewHypertension200750118118817502490
   PubMed Web of Science ®Google Scholar
• ManciaGSchumacherHIncidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trialsPatient Prefer Adherence201261922272064
   PubMed Web of Science ®Google Scholar
• EspostiLDSaragoniSBenemeiSAdherence to antihypertensive medications and health outcomes among newly treated hypertensive patientsClinicoecon Outcomes Res20113475421935332
   PubMedGoogle Scholar
• MazzagliaGAmbrosioniEAlacquaMAdherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patientsCirculation2009120161598160519805653
   PubMed Web of Science ®Google Scholar
• CampbellDJA review of perindopril in the reduction of cardiovascular eventsVasc Health Risk Manag20062211712417319455
   PubMedGoogle Scholar
• OvbiageleBDienerHCYusufSLevel of systolic blood pressure within the normal range and risk of recurrent strokeJAMA2011306192137214422089721
   PubMed Web of Science ®Google Scholar
• RobinsonTGPotterJFFordGAEffects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trialLancet Neurol20109876777520621562
   PubMed Web of Science ®Google Scholar
• LiYMaSMDuMChuWWChengXMPerindopril, amlodipine and telmisartan improve arterial stiffness in patients with hypertensionZhonghua Xin Xue Guan Bing Za Zhi2009371090891220137542
   PubMedGoogle Scholar
• NakamuraTKawachiKSaitoYEffects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertensionInt Heart J200950450151219609054
   PubMed Web of Science ®Google Scholar
• CeconiCFoxKMRemmeWJACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENTCardiovasc Res200773123724617140552
   PubMed Web of Science ®Google Scholar
• TardifJCAngiotensin-converting enzyme inhibitors and atherosclerotic plaque: a key role in the cardiovascular protection of patients with coronary artery diseaseEur Heart J Supp200911Suppl EE9E16
   Web of Science ®Google Scholar
• KarlbergBECough and inhibition of the renin-angiotensin systemJ Hypertens Suppl1993113S49SS528315520
   PubMedGoogle Scholar
• BangaloreSKumarSWetterslevJMesserliFHAngiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trialsBMJ2011342d223421521728
   PubMed Web of Science ®Google Scholar
• ReboldiGAngeliFCavalliniCGentileGManciaGVerdecchiaPComparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysisJ Hypertens20082671282128918550998
   PubMed Web of Science ®Google Scholar
• HealeyJSBaranchukACrystalEPrevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysisJ Am Coll Cardiol200545111832183915936615
   PubMed Web of Science ®Google Scholar
• AbuissaHJonesPGMarsoSPO’KeefeJHJrAngiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trialsJ Am Coll Cardiol200546582182616139131
   PubMed Web of Science ®Google Scholar
• StaessenJAWangJGThijsLCardiovascular protection and blood pressure reduction: a meta-analysisLancet200135892901305131511684211
   PubMed Web of Science ®Google Scholar
• van VarkLCBertrandMAkkerhuisKMAngiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patientsEur Heart J201233162088209722511654
   PubMed Web of Science ®Google Scholar
• DonzelliAReduction in all-cause mortality: from ACE inhibitors or from associated drugs?Eur Heart J Epub6252012
   Google Scholar
• SavareseGCostanzoPClelandJGA meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failureJ Am Coll Cardiol201361213114223219304
   PubMed Web of Science ®Google Scholar
• BorzakSRidkerPMDiscordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarctionAnn Intern Med1995123118738777486471
   PubMed Web of Science ®Google Scholar
• FeinsteinARMeta-analysis: statistical alchemy for the 21st centuryJ Clin Epidemiol199548171797853050
   PubMed Web of Science ®Google Scholar
• MesserliFHCase-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into contextAnn Intern Med1995123118888897486476
   PubMed Web of Science ®Google Scholar
• AntoniouTCamachoXYaoZGomesTJuurlinkDNMamdaniMMComparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort studyCMAJ2013185121035104123836857
   PubMed Web of Science ®Google Scholar
• SleightPClinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitorJ Hypertens Suppl2009275S23S2919587551
   PubMedGoogle Scholar